Evra Contraindications

EVRA should not be used in women who currently have the following conditions: Presence or risk of venous thromboembolism (VTE).
Venous thromboembolism - current VTE (on anticoagulants) or history of (e.g. deep venous thrombosis [DVT] or pulmonary embolism [PE]).
Known hereditary or acquired predisposition for venous thromboembolism, such as APC-resistance, (including Factor V Leiden), antithrombin-III-deficiency, protein C deficiency, protein S deficiency.
Major surgery with prolonged immobilization (see Precautions).
A high risk of venous thromboembolism due to the presence of multiple risk factors (see Precautions).
Presense or risk of arterial thromboembolism (ATE).
Arterial thromboembolism - current arterial thromboembolism, history of arterial thromboembolism (e.g. myocardial infarction) or prodromal condition (e.g. angina pectoris).
Cerebrovascular disease - current stroke, history of stroke or prodromal condition (e.g. transient ischaemic attack, TIA).
Known hereditary or acquired predisposition for arterial thromboembolism, such as hyperhomocysteinaemia and antiphospholipid-antibodies (anticardiolipin-antibodies, lupus anticoagulant).
History of migraine with focal neurological symptoms.
A high risk of arterial thromboembolism due to multiple risk factors (see Precautions) or to the presence of one serious risk factor such as: Diabetes mellitus with vascular symptoms; Severe hypertension (Persistent blood pressure values of ≥ 160 mm Hg systolic or ≥ 100 mm Hg diastolic); Severe dyslipoproteinaemia.
Valvular heart disease with complications.
Known or suspected carcinoma of the breast.
Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia.
Undiagnosed abnormal genital bleeding.
Cholestatic jaundice of pregnancy or jaundice with prior hormonal contraceptive use.
Acute or chronic hepatocellular disease with abnormal liver function.
Hepatic adenomas or carcinomas.
Known or suspected pregnancy.
Hypersensitivity to any component of this product.
Patients receiving drug combinations with paritaprevir/ritonavir, ombitasvir, and/or dasabuvir due to potential for ALT elevations.